These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 26702784)

  • 1. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
    Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
    Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression.
    Gahr S; Mayr C; Kiesslich T; Illig R; Neureiter D; Alinger B; Ganslmayer M; Wissniowski T; Fazio PD; Montalbano R; Ficker JH; Ocker M; Quint K
    Int J Oncol; 2015 Sep; 47(3):963-70. PubMed ID: 26202945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
    PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression.
    Yao ZG; Li WH; Hua F; Cheng HX; Zhao MQ; Sun XC; Qin YJ; Li JM
    J Neuropathol Exp Neurol; 2017 Dec; 76(12):1000-1007. PubMed ID: 29136455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis.
    Di Fazio P; Schneider-Stock R; Neureiter D; Okamoto K; Wissniowski T; Gahr S; Quint K; Meissnitzer M; Alinger B; Montalbano R; Sass G; Hohenstein B; Hahn EG; Ocker M
    Cell Oncol; 2010 Jan; 32(4):285-300. PubMed ID: 20208142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines.
    Henrici A; Montalbano R; Neureiter D; Krause M; Stiewe T; Slater EP; Quint K; Ocker M; Di Fazio P
    Mol Carcinog; 2015 Aug; 54(8):585-97. PubMed ID: 24375802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
    PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer.
    Di Fazio P; Waldegger P; Jabari S; Lingelbach S; Montalbano R; Ocker M; Slater EP; Bartsch DK; Illig R; Neureiter D; Wissniowski TT
    Oncotarget; 2016 May; 7(20):28998-9010. PubMed ID: 27058414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y; Liu W; Zhang L; Jia G
    Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines.
    Zopf S; Ocker M; Neureiter D; Alinger B; Gahr S; Neurath MF; Di Fazio P
    BMC Cancer; 2012 Sep; 12():386. PubMed ID: 22943463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.
    Di Fazio P; Montalbano R; Neureiter D; Alinger B; Schmidt A; Merkel AL; Quint K; Ocker M
    Exp Cell Res; 2012 Sep; 318(15):1832-43. PubMed ID: 22683924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
    Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
    Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
    Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
    Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.